Compare ALT & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALT | NEWT |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 395.5M |
| IPO Year | 2005 | N/A |
| Metric | ALT | NEWT |
|---|---|---|
| Price | $3.28 | $12.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $17.67 | $15.33 |
| AVG Volume (30 Days) | ★ 2.6M | 223.6K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.24% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.45 |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.87 | $9.51 |
| 52 Week High | $7.73 | $14.91 |
| Indicator | ALT | NEWT |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 62.38 |
| Support Level | $2.87 | $11.24 |
| Resistance Level | $4.25 | $14.91 |
| Average True Range (ATR) | 0.16 | 0.37 |
| MACD | 0.05 | 0.21 |
| Stochastic Oscillator | 60.45 | 99.77 |
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.